Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Take it Off! | Main | Gumming Up the Amyloid Works »

November 8, 2004

Merck's State of Mind

Email This Entry

Posted by Derek

It may not be known outside the industry, but what Merck is going through right now must be particularly painful just because it's happening to Merck. Now, as I mentioned the other day, I have a lot of respect for the company and for many of the people who work there. (See "Let's See What the Sharks Think of These Steaks!" on Nov. 2nd, below.) But no one in the business would deny that Merck has always considered itself a bit elevated from the common herd. Sometimes that's been justified, sometimes not. But with that attitude in place, which it has been for decades, the company's troubles must be even harder to confront.

Other companies have had painful near-death experiences, of course, and their corporate cultures reflect it. At a place that's been through a major episode, you can pick up defiant we-survived-that-and-we'll-survive-this-too music, and philosophical all-things-must-pass stuff, too. But the one thing that everyone at such a company knows is that all things can come to pass, that terrible problems can come flapping and screeching down with no warning. They know that they're not immune.

I'm not completely sure that everyone at Merck had internalized that. To be sure, the last couple of years have been pretty rocky over there, with several advanced clinical candidates disappearing amid bonfires of money. But those are jsut the normal breaks of the drug-discovery game, unfortunately, and they probably weren't enough to shake Merckian confidence. After all, if a compound runs into esoteric trouble late in the clinic, how were you to know? That's what research is for!

But Vioxx, now that's a different story. "How were we supposed to know?" is not a rhetorical question any more. Highly motivated lawyers are lining up to try to prove just how Merck was supposed to know. They'll be hammering away at themes of negligence and incompetence, of conspiracy and culpability. I don't know if the effort will succeed, (although those internal memos that have surfaced makes rethink the odds), but the pummeling that Merck is going to get will surely have an effect.

In the end, Merck is likely going to have to emit ten to twenty billion dollars. But that's not the effect that I was talking about. That's just money - well, just an awful lot of money - and they could conceivably earn it back, given the time and luck for a brutal retrenchment. (We'll leave aside for now the question of whether there's enough of either available.) But Merck's good name is in for a trampling, as is Merck's confidence. There are probably plenty of people there who don't realize yet just how thoroughly both of those are being lost.

Comments (0) + TrackBacks (0) | Category: Drug Industry History


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern